PIERRE, S.D.—South Dakota Attorney General Marty Jackley has joined a multistate effort seeking court approval of settlements with three generic drug manufacturers accused of conspiring to inflate prices and restrict competition.
The settlements involve Ascend Laboratories, Citron Pharma and Mayne Pharma and are part of a broader antitrust case being pursued by 45 states and territories.
Ascend has agreed to pay $400,000 to participating states, while Mayne will pay $650,000. Citron, which has ceased operations, agreed to non-monetary terms.
South Dakota will receive payments from Ascend and Mayne. Mayne will pay the state $462.73, with another $223.95 going to Medicaid. Ascend will pay South Dakota $284.76, with Medicaid receiving an additional $137.81.
The state’s share will be deposited into the Attorney General’s Antitrust Fund.
The companies also agreed to internal reforms intended to promote compliance with antitrust laws and prevent future anti-competitive conduct.
Jackley said the settlements are part of a continuing effort by attorneys general to hold generic drug companies accountable for alleged price fixing and return money to consumers who were affected.
The agreements follow earlier settlements with Sandoz, Glenmark, Lannett, Bausch, Apotex, Heritage and Heritage parent company Emcure. Those settlements totaled $496.5 million.
The states are also preparing for the first trial in the broader litigation, which is scheduled to begin in Hartford, Connecticut, in February 2027.
Consumers who purchased certain generic prescription drugs between May 2009 and December 2019 may be eligible for compensation from the settlements.